Suppr超能文献

玻璃体内注射更昔洛韦治疗急性视网膜坏死

[Intravitreal injection of Ganciclovir in the treatment of acute retinal necrosis].

作者信息

Guo Li-bin, Sun Ding, Ye Jun-jie, Geng Shuang, Xu Hai-yan, Zhang Mei-fen

机构信息

Department of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College, Eye Research Center of Chinese Academy of Medical Sciences, Beijing 100730, China.

出版信息

Zhonghua Yan Ke Za Zhi. 2007 Jul;43(7):631-7.

Abstract

OBJECTIVE

To evaluate the indication and clinical effects of intravitreal injection of Ganciclovir in the treatment of acute retinal necrosis (ARN).

METHODS

Fourteen cases (14 eyes) of ARN which were consistent with the diagnostic criteria of American Uveitis Society were enrolled. Preoperative visual acuity was: light perception, hand movement and counting fingers (CF), each in 1 eye; 0.08 - 0.1 in 4 eyes; 0.2 - 0.4 in 5 eyes 0.5 in 1 eye and 0.8 in 1 eye. Keratic precipitate and aqueous flare were presented in the anterior segment. Peripheral focal and/or patch retinal necrosis, retinal occlusive arteritis and retinal hemorrhage were observed in the fundus. Acyclovir or Ganciclovir was administrated systematically by intravenous injection. The condition of 14 eyes deteriorated underwent intravitreal injection of Ganciclovir but without retinal detachment. After intravitreal injection 2 eyes became worse and underwent vitrectomy for PVR and retinal detachment. The follow-up time varied from 4 to 74 months (mean 25 months).

RESULTS

The inflammation of anterior segment and vitreoretinopathy of 14 cases disappeared after intravitreal injection of Ganciclovir. The visual acuity markedly increased in 12 eyes without surgical intervention. Visual acuity achieved 1.0 - 1.5 in 5 eyes, 0.5 - 0.9 in 5 eyes and 0.3 in 2 eyes after intravitreal injection of Ganciclovir. The retina of the 2 eyes undergone vitrectomy was reattached and their visual acuity improved from CF to 0.4 and LP to CF, respectively.

CONCLUSIONS

In ARN patients whose conditions could not be controlled by systemic antivirus medicine treatment, early intravitreal injection of Ganciclovir can yield satisfactory therapeutic effects and better visual prognoses if applied before the occurrence of PVR or retinal detachment.

摘要

目的

评估玻璃体内注射更昔洛韦治疗急性视网膜坏死(ARN)的适应证及临床效果。

方法

纳入14例(14只眼)符合美国葡萄膜炎学会诊断标准的ARN患者。术前视力情况为:1只眼光感,1只眼手动,1只眼数指;4只眼视力为0.08 - 0.1;5只眼视力为0.2 - 0.4;1只眼视力为0.5;1只眼视力为0.8。前段可见角膜后沉着物及房水闪光。眼底可见周边灶状和/或片状视网膜坏死、视网膜闭塞性动脉炎及视网膜出血。给予阿昔洛韦或更昔洛韦静脉系统用药。14只病情恶化的眼睛接受了玻璃体内注射更昔洛韦,但未发生视网膜脱离。玻璃体内注射后,2只眼病情加重,因发生增殖性玻璃体视网膜病变(PVR)和视网膜脱离而接受了玻璃体切除术。随访时间为4至74个月(平均25个月)。

结果

玻璃体内注射更昔洛韦后,14例患者的前段炎症和玻璃体视网膜病变均消失。12只眼未经手术干预视力显著提高。玻璃体内注射更昔洛韦后,5只眼视力达到1.0 - 1.5,5只眼视力为0.5 - 0.9,2只眼视力为0.3。接受玻璃体切除术的2只眼视网膜复位,视力分别从数指提高到0.4,从光感提高到数指。

结论

对于全身抗病毒药物治疗无法控制病情的ARN患者,在PVR或视网膜脱离发生前尽早玻璃体内注射更昔洛韦可取得满意的治疗效果及较好的视力预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验